Peptide inhibitors of hepatitis c virus ns3 protease
CA 2330247 A1 · Owner: Poma, Marco · Inventors: Narjes, Frank; Poma, Marco; Koehler, Konrad
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Fluorinated oligopeptides, especially those having 4,4-difluoro-2-amino butyric acid at the C terminus, may be effective inhibitors of hepatitis C virus NS3 protease. Examples of hexapeptides of the invention optimised for , binding in the S1 specificity pocket of the enzyme may display IC50s at the , sub-micromolar level. Embodiments of tripeptides of the invention having a , keto-acid group at the C-terminus are likewise, potent inhibitors of NS3 , protease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 9, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 9, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 9, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.